TD Asset Management Inc. Reduces Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

TD Asset Management Inc. cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 463,961 shares of the company's stock after selling 39,113 shares during the period. TD Asset Management Inc. owned about 1.49% of Medpace worth $154,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. EntryPoint Capital LLC raised its position in Medpace by 67.4% during the fourth quarter. EntryPoint Capital LLC now owns 1,503 shares of the company's stock valued at $499,000 after acquiring an additional 605 shares in the last quarter. Congress Wealth Management LLC DE lifted its stake in shares of Medpace by 1.7% in the 4th quarter. Congress Wealth Management LLC DE now owns 12,288 shares of the company's stock valued at $4,082,000 after purchasing an additional 209 shares during the period. Summit Creek Advisors LLC boosted its holdings in Medpace by 0.3% during the fourth quarter. Summit Creek Advisors LLC now owns 47,808 shares of the company's stock worth $15,883,000 after buying an additional 146 shares in the last quarter. Vanguard Group Inc. grew its position in Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock valued at $854,087,000 after buying an additional 25,704 shares during the period. Finally, LPL Financial LLC raised its position in shares of Medpace by 5.3% in the fourth quarter. LPL Financial LLC now owns 17,960 shares of the company's stock worth $6,010,000 after acquiring an additional 909 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Finally, Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $376.30.

Medpace Stock Performance

MEDP traded down $4.25 during trading on Friday, hitting $312.36. The stock had a trading volume of 343,137 shares, compared to its average volume of 298,736. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77. The firm has a market capitalization of $9.52 billion, a P/E ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47. The company's 50-day moving average price is $335.90 and its 200 day moving average price is $339.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.